3.3. Targeted FLT3 Inhibitors in AML: Clinical Efficacy and Evolution of Treatment Landscape with Midostaurin, Gilteritinib, Quizartinib, and Emerging Role of Crenolanib. Here, FLT3 is linked to acute myeloid leukemia.